Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

High levels of ammonia kill liver cells by damaging the mitochondria that power the cells. But this can be prevented using an existing drug due to start clinical trials, finds a new study in mice.

In this pilot study, we demonstrated that oral undenatured cysteine-rich whey protein isolate supplementation for 12 weeks was associated with significant biochemical and metabolic improvement in ...

NASH diagnostics consists of CK-18 total, CK-18 cleaved, adiponectin and resistin. NASH diagnostic panel consists of diabetes, gender, BMI, triglyceride and CK-18 total, CK-18 cleaved levels.

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated with significant global public health concerns.

Roche’s Genentech unit bought Jecure Therapeutics and its portfolio of NLRP3 drugs in 2018, focusing on peripheral drugs for NASH, liver fibrosis, gout, inflammatory bowel disease, and ...

Objective Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor expressed in tissues with high oxidative activity that plays a central role in metabolism. In this work, we ...